Ben Hargreaves looks at why insulin’s price is so controversial and whether ... The non-profit drugmaker plans to launch biosimilars of Sanofi’s Lantus (insulin glargine), Novo Nordisk ...

A law that coaxed companies to lower the price of drugs came with a little-known consequence: smaller discounts for ...

The city school system alleges that drug manufacturers raised the price of insulin to win the business of pharmacy benefits managers — intermediary companies that negotiate prices between ...

The average price per insulin unit hit a 10-year low in 2024, largely driven by federal actions and voluntary price cuts from drugmakers, according to a Jan. 15 GoodRx report. GoodRx analyzed the ...

Indianapolis-based drugmaker Eli Lilly and Company has announced price ... (insulin glargine-aglr) injection, a basal insulin that is biosimilar to and interchangeable with Lantus (insulin ...

COLUMBUS, Ohio — The City of Columbus is suing pharmaceutical companies and middlemen known as pharmacy benefit managers, claiming they artificially inflated insulin prices, costing the city ...

A 2020 law aimed partially at bringing down insulin prices allowed Newsom to negotiate ... meaning it can be substituted at the pharmacy for Lantus, the brand name insulin glargine, without ...

California Governor Gavin Newsom's bold plan to produce cheap, generic insulin for Californians by 2024 could be delayed for years. Civica, the nonprofit drug manufacturer contracted to produce ...

Biocon share price surged 4.5% during Monday's session following the clearance from the US Food and Drug Administration (US FDA) for the insulin facility of Biocon Biologics in Malaysia.